Screener
Vera Therapeutics VERA Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $86,011 | $41,278 |
| General and administrative | 39,121 | 15,916 |
| Total operating expenses | 125,132 | 57,194 |
| Loss from operations | (125,132) | (57,194) |
| Other income (expense): | ||
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's total operating expenses?
- Vera Therapeutics (VERA) reported total operating expenses of $125.13M in Q1 2026.
- How has Vera Therapeutics's total operating expenses changed year-over-year?
- Vera Therapeutics's total operating expenses increased by 118.8% year-over-year, from $57.19M to $125.13M.
- What is the long-term trend for Vera Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Vera Therapeutics's total operating expenses has grown at a 74.0% compound annual growth rate (CAGR), from $34.4M to $315.47M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Vera Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude